A Case of Dystrophic Epidermolysis Bullosa Improved with Etanercept for Concomitant Psoriatic Arthritis
A Case of Dystrophic Epidermolysis Bullosa Improved with Etanercept for Concomitant Psoriatic Arthritis
复制标题
DOI：
10.2165/1153427-s0-000000000-00000
复制
发表时间：
2010-01-01
影响因子：
7.3
通讯作者：
Pacifico, Valeria
中科院分区：
文献类型：
--
作者：
Gubinelli, Emanuela;Angelo, Corrado;Pacifico, Valeria
大疱性表皮病是一组遗传性、慢性、非炎症性皮肤病，营养不良性大疱性表皮病（DEB）是最严重的变体之一。肿瘤坏死因子α（TNF α）在DEB发病机制中的作用尚未报道。据报道，一个DEB病例似乎对TNF α抑制剂依那西普治疗伴发的银屑病关节炎反应良好。在治疗的前3个月内，DEB的进展性改善是明显的，并且在治疗的3年内，注意到DEB的持续良好控制。DEB改善和依那西普之间的相关性尚未确定，但该病例可能提供对DEB因果机制的深入了解。
Epidermolysis bullosa is a group of inherited, chronic, non-inflammatory skin disorders, and dystrophic epidermolysis bullosa (DEB) is one of the most severe variants. The role of tumour necrosis factor alpha (TNF alpha) has not been reported in the pathogenesis of DEB. A DEB case is reported that appears to have responded well to the TNF alpha inhibitor etanercept given for the treatment of concomitant psoriatic arthritis. A progressive improvement in DEB was apparent over the first 3 months of treatment and persistent good control of DEB was noted over 3 years of therapy. A correlation between DEB improvement and etanercept has not been made, but the case may provide insight into the causal mechanisms of DEB.